Bill > SB00451

This bill establishes an advisory council on chimeric antigen receptor T-cell therapy and other gene therapies, which are advanced treatments for cancer. This council will advise the Department of Public Health and other state agencies on various aspects of these therapies, including their availability, safe and equitable delivery, provider training, patient follow-up, referral protocols, patient and caregiver education about costs and insurance coverage, coordination with research and government entities like the Centers for Medicare & Medicaid Services (CMS), development of specialized treatment centers, creation of a statewide referral network, safety protocols for complications, psychosocial support for patients, and tracking patient outcomes with a focus on equity across different demographics. The council will also consult with experts, hold public hearings, and research ways to improve patient access. Its membership will include state commissioners, legislative committee members, and appointed individuals with expertise in medicine, patient advocacy, health insurance, and life sciences. The council will be within the Department of Public Health for administrative purposes and will report its findings and recommendations annually to the legislature, starting one year after its first meeting, which is scheduled to occur by November 30, 2026. The council can also accept grants and donations to support its work.